- Home
- ANVS vs BOLD Comparison
ANVS vs BOLD Comparison
Compare ANVS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANVS | BOLD |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 25.7M |
| IPO Year | 2019 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ANVS | BOLD |
|---|---|---|
| Price | $2.03 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $13.50 | $4.00 |
| AVG Volume (30 Days) | ★ 359.7K | 47.1K |
| Earning Date | 03-16-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.96 |
| 52 Week High | $5.50 | $1.78 |
Technical Indicators
Market Signals| Indicator | ANVS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 44.32 |
| Support Level | $1.97 | $1.10 |
| Resistance Level | $2.99 | $1.20 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 1.89 | 15.00 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.